Endo International PLC

Endo International — UBS Healthcare Conference 2017

23 slides from Endo International's conference presentation, May 23, 2017

  1. Slide 1: Endo International plc UBS Healthcare Conference

    Slide 1: Endo International plc UBS Healthcare Conference

    Endo International plc UBS Healthcare Conference May 23, 2017 ©2017 Endo Pharmaceuticals Inc. All rights reserved. Exhibit 99.1

  2. Slide 2: Forward Looking Statements; Non-GAAP Financial Measures

    Slide 2: Forward Looking Statements; Non-GAAP Financial Measures

    Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. Statements including words such as “believes,” “expects,” “anticipates,” “inte

  3. Slide 3: Endo Overview

    Slide 3: Endo Overview

    Endo Overview ©2017 Endo Pharmaceuticals Inc. All rights reserved. Q1 2017 Total Sales: $1,038m U.S. Generic Pharmaceuticals: U.S. Branded Pharmaceuticals: International Pharmaceuticals: $250m $722m $65m U.S. Generic Pharmaceuticals Differentiated technologies Strong pipeline of FTFs and ANDAs 4th l

  4. Slide 4: Our Priorities for 2017 and Beyond

    Slide 4: Our Priorities for 2017 and Beyond

    1 Reshape our Organization for Success Focus on differentiated/intelligent product selection Drive EBITDA margin improvements through operational execution and continuous improvements De-lever 3-4x range over time; committed to a highly disciplined capital allocation approach 3 Drive Margin Expansio

  5. Slide 5: U.S. Generics: Overview

    Slide 5: U.S. Generics: Overview

    U.S. Generics: Overview ©2017 Endo Pharmaceuticals Inc. All rights reserved. Q1 2017 Rev. Q1 2016 Rev. YoY ∆%* U.S. Generics Base $236 $347 (32%) Sterile Injectables $151 $124 22% New Launches & Alternative Dosages $334 $112 198% Q1 2017 U.S. Generics Sales: $722m U.S. Generics Base Sterile Injectab

  6. Slide 6: U.S. Generics: Full Suite of Technology Capabilities with a Robust Pipeline

    Slide 6: U.S. Generics: Full Suite of Technology Capabilities with a Robust Pipeline

    U.S. Generics: Full Suite of Technology Capabilities with a Robust Pipeline Endo has become a more diversified company with expanded and differentiated capabilities, including polypeptides Highly compliant manufacturing with annual capacity of ~20 billion extended units Tablets (IR / ER) Bupropion E

  7. Slide 7: U.S. Generics: 2017 Progress and Select Milestones

    Slide 7: U.S. Generics: 2017 Progress and Select Milestones

    U.S. Generics: 2017 Progress and Select Milestones ©2017 Endo Pharmaceuticals Inc. All rights reserved. * Market value defined by IMS sales for 12 months Select Potential FTF/FTM Opportunities SABRIL® (vigabatrin for oral solution) – received FDA approval – launch in 2017 PYLERA® (bismuth subcitrate

  8. Slide 8: U.S. Branded: Overview

    Slide 8: U.S. Branded: Overview

    U.S. Branded: Overview [1] Products included within Other Specialty include TESTOPEL®, NASCOBAL® Nasal Spray, and AVEED®. [2] Products included within Established Products include legacy pain products OPANA® ER, PERCOCET®, VOLTAREN® Gel, LIDODERM as well as other established products including, but

  9. Slide 9: U.S. Branded: XIAFLEX in Cellulite

    Slide 9: U.S. Branded: XIAFLEX in Cellulite

    U.S. Branded: XIAFLEX® in Cellulite ©2017 Endo Pharmaceuticals Inc. All rights reserved. Data presented at Aesthetica Super Symposium (American Society of Plastic Surgeons) and American Academy of Dermatology (AAD) Plans to initiate Ph3 in 2H 2017 Commercial assessment ongoing – we are preparing to

  10. Slide 10: International Pharmaceuticals: Overview

    Slide 10: International Pharmaceuticals: Overview

    International Pharmaceuticals: Overview ©2017 Endo Pharmaceuticals Inc. All rights reserved. Q1 2017 Rev. Q1 2016 Rev. YoY ∆%* Paladin & other[1] $29 $34 (13%) Litha & Somar $36 $37 (4%) Q1 2017 International Sales: $65m Paladin & other[1] Litha & Somar [1] Includes sales from Endo Ventures Limited

  11. Slide 11: Q1 2017: Financial Results (Adjusted Continuing Operations)

    Slide 11: Q1 2017: Financial Results (Adjusted Continuing Operations)

    Q1 2017: Financial Results (Adjusted Continuing Operations)[1][2] ©2017 Endo Pharmaceuticals Inc. All rights reserved. (US $M) Q1 2017 Q1 2016 Y/Y change Revenue $1,038 $964 8% Gross Margin 61.1% 59.5% 160 bps Operating Income $437 $359 22% Income from Continuing Operations $275 $241[3] 14% Effectiv

  12. Slide 12: 2017 Financial Guidance (Continuing Operations)

    Slide 12: 2017 Financial Guidance (Continuing Operations)

    2017 Financial Guidance (Continuing Operations*) ©2017 Endo Pharmaceuticals Inc. All rights reserved. * Continuing Operations includes Endo and Par and excludes ASTORA (formerly known as AMS Women’s Health) Measure FY 2017 Financial Guidance Revenue $3.45B - $3.60B Adjusted EBITDA $1.50B - $1.58B Ad

  13. Slide 13: Our Priorities for 2017 and Beyond

    Slide 13: Our Priorities for 2017 and Beyond

    1 Reshape our Organization for Success Focus on differentiated/intelligent product selection Drive EBITDA margin improvements through operational execution and continuous improvements De-lever 3-4x range over time; committed to a highly disciplined capital allocation approach 3 Drive Margin Expansio

  14. Slide 14: Endo International plc UBS Healthcare Conference

    Slide 14: Endo International plc UBS Healthcare Conference

    Endo International plc UBS Healthcare Conference May 23, 2017 ©2017 Endo Pharmaceuticals Inc. All rights reserved.

  15. Slide 15: Appendix

    Slide 15: Appendix

    Appendix ©2017 Endo Pharmaceuticals Inc. All rights reserved.

  16. Slide 16: 2017: Cash Flow Update

    Slide 16: 2017: Cash Flow Update

    2017: Cash Flow Update [1] FY ’17 Guidance includes restructuring and integration related costs of ~$30M of restructuring expenses related primarily to the Pain/Branded Restructuring, ~$20M of Severance costs related to the Corporate and R&D restructuring, ~$20M in restructuring costs related to the

  17. Slide 17: Debt Refinancing Results in Enhanced Operational Flexibility

    Slide 17: Debt Refinancing Results in Enhanced Operational Flexibility

    Debt Refinancing Results in Enhanced Operational Flexibility ©2017 Endo Pharmaceuticals Inc. All rights reserved. Maturity Profile prior to Refinancing ($ millions) Maturity Profile after Refinancing ($ millions) Summary In April 2017, Endo announced debt refinancing Issued a new ~$3.4 billion 7-yea

  18. Slide 18: U.S. Generics: Competitive Advantage

    Slide 18: U.S. Generics: Competitive Advantage

    U.S. Generics: Competitive Advantage BENEFITS of a Big Generic Company Breadth of Product Portfolio Strong Trade Presence Established Corporate Infrastructure With the STRENGTHS of an Agile Company Every Product is Important Focused on US Market Quick Decision Making Ability to Execute Quickly ©2017

  19. Slide 19: Cash Conversion Cycle

    Slide 19: Cash Conversion Cycle

    Cash Conversion Cycle ©2017 Endo Pharmaceuticals Inc. All rights reserved.

  20. Slide 20: Reconciliation of Non-GAAP Measures

    Slide 20: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures ©2017 Endo Pharmaceuticals Inc. All rights reserved.

  21. Slide 21: Reconciliation of Non-GAAP Measures

    Slide 21: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures ©2017 Endo Pharmaceuticals Inc. All rights reserved.

  22. Slide 22: Reconciliation of Non-GAAP Measures

    Slide 22: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures ©2017 Endo Pharmaceuticals Inc. All rights reserved.

  23. Slide 23: Reconciliation of Non-GAAP Measures

    Slide 23: Reconciliation of Non-GAAP Measures

    Reconciliation of Non-GAAP Measures ©2017 Endo Pharmaceuticals Inc. All rights reserved.

Source: SEC EDGAR · 8-K filed May 23, 2017

More decks from Endo International PLC